Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD79A Double Nickase Plasmid (h): sc-401827-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD79A Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD79A Double Nickase Plasmid (h) and CD79A Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD79A. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD79A Antibody (HM47): sc-20064
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD79A Double Nickase Plasmid (h) | sc-401827-NIC | 20 µg | $410.00 | |||
CD79A Double Nickase Plasmid (h2) | sc-401827-NIC-2 | 20 µg | $410.00 |
CD79A encodes the Ig-alpha subunit of the B cell antigen receptor (BCR) complex, forming a signaling heterodimer with CD79B that couples antigen engagement to intracellular activation cascades. Through its immunoreceptor tyrosine-based activation motifs (ITAMs), CD79A supports phosphorylation-dependent recruitment of SYK and propagation of downstream pathways including PI3K–AKT, NF-κB, and MAPK, shaping B cell development, activation, and survival. Altered CD79A expression or signaling competence is associated with dysregulated BCR signaling networks implicated in B cell immunodeficiencies and B cell malignancy biology. As a lineage-restricted marker, CD79A is also widely used to interrogate B cell identity, differentiation states, and antigen-driven signaling responses in human immune models.
CD79A Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD79A locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD79A. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD79A function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD79A-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.